Establishment and identification of the human multi-drugresistant cholangiocarcinoma cell line QBC939/ADM

Molecular Biology Reports

Volumn 38, Issue 5, 2011, Pages 3075-3082

  Liu, Zhi Hua ^a   He, Yan Ping ^b   Zhou, Yukun ^a   Zhang, Peng ^a   Qin, Huanlong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Multidrug resistant; P glycoprotein

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MITOMYCIN; VINDESINE;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL SHAPE; CELL STRAIN QBC939; CELL STRAIN QBC939/ADM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL CYCLE; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; MITOMYCIN; P-GLYCOPROTEIN; VINDESINE;

EID: 80052451114     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-9975-7     Document Type: Article

References (42)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368-1378
2. Lazaridis KN, Gores GJ (2005) Cholangiocarcinoma. Gastroenterology 128:1655-1667 (Pubitemid 40692558)
3. Hur H, Park IY, Sung GY, Lee DS, Kim W, Won JM (2009) Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones. Asian J Surg 32:7-12
4. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507-517 (discussion 517- 509)
5. Weber SM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR (2002) Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 235:392-399 (Pubitemid 34183890)
6. Todoroki T, Kawamoto T, Koike N, Fukao K, Shoda J, Takahashi H (2001) Treatment strategy for patients with middle and lower third bile duct cancer. Br J Surg 88:364-370 (Pubitemid 32238697)
7. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD, Cameron JL (1995) Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221:788-797 (discussion 797-788)
8. Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H (2005) Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 35:548-552 (Pubitemid 40854019)
9. Shinchi H, Takao S, Nishida H, Aikou T (2000) Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol 75:89-94
10. Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF (1996) A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 39:852-855 (Pubitemid 27049089)
11. Sirica AE (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5-15 (Pubitemid 40066375)
12. Kaassis M, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R, Canard JM, Fritsch J, Rey JF, Burtin P (2003) Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 57:178-182 (Pubitemid 36236755)
13. Chang WH, Kortan P, Haber GB (1998) Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 47:354-362 (Pubitemid 28237504)
14. Prat F, Chapat O, Ducot B, Ponchon T, Fritsch J, Choury AD, Pelletier G, Buffet C (1998) Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 42:76-80 (Pubitemid 28228391)
15. Figueras J, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, Rafecas A, Torras J, Jaurrieta E (2000) Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl 6:786-794
16. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685-1695
17. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 92:1650-1654 (Pubitemid 40756474)
18. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600 (Pubitemid 26285639)
19. Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115-125 (Pubitemid 38738341)
20. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, Scheper RJ (2002) Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 82:193-201 (Pubitemid 34160456)
21. Derome A, Hoischen C, Bussiek M, Grady R, Adamczyk M, Kedzierska B, Diekmann S, Barilla D, Hayes F (2008) Centromere anatomy in the multidrug-resistant pathogen Enterococcus faecium. Proc Natl Acad Sci USA 105:2151-2156 (Pubitemid 351439480)
22. Fricke WF, Welch TJ, McDermott PF, Mammel MK, LeClerc JE, White DG, Cebula TA, Ravel J (2009) Comparative genomics of the IncA/C multidrug resistance plasmid family. J Bacteriol 191:4750-4757
23. Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, Tamaki N, Iwaisako K, Kitamura K, Ikai I, Uemoto S (2009) Pglycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 34:1303-1312
24. Kerb R, Hoffmeyer S, Brinkmann U (2001) ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2:51-64 (Pubitemid 32633651)
25. Hooiveld GJ, van Montfoort JE, Meijer DK, Muller M (2001) Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur J Pharm Sci 12:525-543 (Pubitemid 32166751)
26. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI (2006) Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 61:280-288 (Pubitemid 43382627)
27. Ito F, Cho CS, Rikkers LF, Weber SM (2009) Hilar cholangiocarcinoma: current management. Ann Surg 250:210-218
28. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50:808-814
29. Ramacciato G, Nigri G, Ravaioli M, Del Gaudio M (2009) In favor of the Jarnagin-Blumgart classification. Ann Surg 249:697-698 (author reply 698-699)
30. Han P, Kang JH, Li HL, Hu SX, Lian HH, Qiu PP, Zhang J, Li WG, Chen QX (2009) Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. Biochem Biophys Res Commun 385:251-256
31. Incles CM, Schultes CM, Kelland LR, Neidle S (2003) Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. Mol Pharmacol 64:1101-1108 (Pubitemid 37310743)
32. Liu Z-H, He Y-P, Qin H (2009) The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep. doi: 10.1007/s11033-009-9801-2
33. Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, Ying G, Zhang N, Niu R (2009) Anxa2 plays a critical role in enhanced invasiveness of the multi-drug resistant human breast cancer cells. J Proteome Res 8(11):5041-5047
34. Park KH, Seol JY, Yoo CG, Kim YW, Han SK, Lee EH, Kim CM, Shim YS, Lee CT (2001) Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer 31:149-155
35. Kong X, Ge H, Chen L, Liu Z, Yin Z, Li P, Li M (2009) Gammalinolenic acid modulates the response of multidrug-resistant K562 leukemic cells to anticancer drugs. Toxicol In Vitro 23:634-639
36. Yoshino T, Hirabe H, Takahashi M, Kuhara M, Takeyama H, Matsunaga T (2008) Magnetic cell separation using nano-sized bacterial magnetic particles with reconstructed magnetosome membrane. Biotechnol Bioeng 101:470-477
37. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor. J Clin Oncol 27(34):5800-5807
38. Jarnagin WR, Schwartz LH, Gultekin DH, Gonen M, Haviland D, Shia J, D'Angelica M, Fong Y, Dematteo R, Tse A, Blumgart LH, Kemeny N (2009) Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 20:1589-1595
39. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A III, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 247:507-515
40. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, Lie BA (2008) Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 47:90-96 (Pubitemid 351171045)
41. Onori P, DeMorrow S, Gaudio E, Franchitto A, Mancinelli R, Venter J, Kopriva S, Ueno Y, Alvaro D, Savage J, Alpini G, Francis H (2009) Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. Int J Cancer 125:565-576
42. Liu B, Herve J, Bioulac-Sage P, Valogne Y, Roux J, Yilmaz F, Boisgard R, Guettier C, Cales P, Tavitian B, Samuel D, Clerc J, Brechot C, Faivre J (2007) Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma. Gastroenterology 132:1495-1503 (Pubitemid 46656254)